The ability of SPAG5 to modulate the activity of the TP53 pathway, particularly through interactions that lead to downregulation or functional inhibition of pathway components, supports its potential as a target for therapeutic strategies aimed at enhancing the tumour-suppressive capabilities of this pathway. Here, TP53 is linked to neoplasm.